All In MedTech

FDA Clearance Tracker · P010029-S008

EUFLEXXA (1% SODIUM HYALURONATE)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 11, 2011 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 11, 2011

Approved

Time to decision

925 days

Received Mar 30, 2009. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P010029-S008
Device name
EUFLEXXA (1% SODIUM HYALURONATE)
Applicant location
Parsippany, NJ
Received
Mar 30, 2009
Decided
Oct 11, 2011
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P010029

Device type

Device class
Class III

Every decision under product code MOZ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR EUFLEXXA (1% SODIUM HYALURONATE). THIS DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVENON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN).

Source documents

Other decisions for Ferring Pharmaceuticals, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.